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Abstract : Interleukin （IL）-4 exhibits strong antitumor effects and IL-4 gene 
therapy has been used clinically in the treatment of some types of cancer.  In 
the present study, we evaluated the efcacy of IL-4-transduced tumor cell vac-
cines in combination with blockade of programmed cell death 1 （PD-1） and 
investigated the mechanisms underlying the antitumor effects of this therapy.  
A poorly immunogenic murine colorectal cancer cell line （i.e. MC38） was 
transduced to overexpress IL-4.  In a therapeutic model, MC38-IL4 cells and 
anti-PD-1 antagonistic antibodies （Ab） were inoculated into parental tumor-
bearing mice.  Immunohistochemical analyses and tumor-specic lysis were also 
performed.  Additive antitumor effects were observed when mice were treated 
with IL-4 in combination with an anti-PD-1 Ab.  Immunohistochemical analysis 
of the therapeutic model showed marked inltration of CD4＋ and CD8＋ cells 
into established MC38 tumors of mice treated with anti-PD-1 Ab.  Signicant 
tumor-specic cytolysis was detected when the splenocytes of mice treated with 
both IL-4 and anti-PD-1 Ab were used as effector cells.  These results suggest 
that blockade of the interaction between PD-1 and programmed death ligand 
1 （PD-L1） enhances the antitumor immune responses induced by IL-4.  Thus, 
IL-4 gene-transduced tumor cell vaccines in combination with PD-1 blockade 
may be considered as possible candidates for clinical trials of new cancer vac-
cines.
Key words : Interleukin-4, Programmed cell death 1, Immunotherapy, Tumor-
based vaccine, Colorectal cancer
Introduction
　Cellular immune responses are thought to be impaired in patients with advanced 
malignant tumors, and tumors are thought to escape immune surveillance by several mecha-
nisms 1, 2）.  To overcome immune suppression in patients or the immune escape of malignant 
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tumors, novel approaches to induce a strong cellular immune response are needed.  Several 
studies in murine models have reported that the cytokine gene transduction of tumor cells 
induces potent antitumor immune responses without systemic adverse effects 3, 4）.  Subcutane-
ous injection of the transduced cells can induce local inammation at the injection site via 
the accumulation of inammatory cells, such as activated natural killer （NK） cells, macro-
phages, dendritic cells （DCs）, and T lymphocytes3, 5, 6）.  Based on these observations, the 
development of vaccinations for clinical use using gene-transduced tumor cells as a vehicle 
to deliver cytokines is an attractive proposition.
　Interleukin （IL）-4, a type 2 response inducer, plays a major role in both B and T cell 
development in the immune system7, 8）.  In addition, it causes a class switch of B cells, 
upregulates major histocompatibility complex （MHC） Class II and adhesion molecules, 
and prevents T cell apoptosis.  With respect to its antitumor effects, IL-4 has been shown 
to have a direct inhibitory effect on tumor cell growth in vivo and in vitro, as well as 
antiangiogenic effects9, 10）.  It has been reported that IL-4 activates endothelia in the 
tumor microenvironment, which results in increased inltration of immune cells 11）.  Other 
reports suggest that eosinophils and neutrophils are responsible for the antitumor effects of 
IL-4 12, 13）.  A recent study has demonstrated that local IL-4 delivery at the site of vaccina-
tion activates local DCs, which play a critical role in the initiation, promotion, and regulation 
of host immune responses and promote T helper （Th） 1 cell responses 4）.  In that study, 
IL-4 appeared to support DC maturation and to enhance IL-12p70 secretion from DCs.  On 
the basis of these ndings supporting the therapeutic effects of IL-4 against tumors, it has 
been used clinically in the treatment of tumors.
　Programmed death 1 （PD-1） was first described as a member of the B7 family of 
costimulatory molecules that modulate T cell antigen-specic receptor signaling and control 
T cell activation, inactivation, and survival14）.  Recently, PD-1 was identied as a marker of 
exhausted T cells in chronic infectious disease15, 16）.  Of the various mechanisms underlying 
tumor-induced immunosuppression by which tumors escape immune surveillance, numerous 
studies have suggested a role for an interaction between PD-1 and programmed death 
ligand 1 （PD-L1） in inhibiting the effector functions of antigen-specic CD8＋ T cells 17, 18）. 
PD-1 is expressed on tumor-inltrating CD8＋ T cells in tumors or on antigen-specic CD8＋ 
T cells in hosts with tumors, and the function of these PD-1＋ T cells is impaired19, 20）. 
PD-L1 has been shown to be expressed at high levels in several different types of cancer 21）, 
and there is a strong correlation between high PD-L1 expression in tumors and a poor 
prognosis22）.  Recent studies have shown that blockade of PD-1–PD-L1 signaling restores 
functional T cell responses in several cancers, subsequently improving clinical outcome 23, 24）.
　In the present study, a preliminary investigation of the effects of combination therapy 
prior to clinical studies, the antitumor effects of a combination of an IL-4-transfected tumor 
cell vaccine and PD-1 blockade were evaluated in a poorly immunogenic murine colorectal 
cancer system.  When parental tumor-bearing mice were injected with IL-4-overexpressing 
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tumor cells and an anti-PD-1-blocking antibody （Ab）, the outgrowth of the established 
parental tumor was signicantly suppressed.  Furthermore, to explore the mechanisms under-
lying the antitumor effects of the IL-4 plus anti-PD-1 combination, tumors were stained 
immunohistologically and we tried to induce tumor-specic T lymphocytes.
Materials and Methods
Mice
　Female 6-week-old C57BL / 6 （B6） mice were purchased from Sankyo Lab Service 
（Tokyo, Japan） for use in experiments when they were 8–12 weeks of age.  Mice were 
maintained in an animal care facility at Showa University.  The present study was approved 
by the Ethics Committee for Animal Experiments of Showa University （permission no. 
2011-1111）.
Cell lines, culture medium, and reagents
　The MC38 murine colorectal adenocarcinoma cell line （B6 mouse origin） and yeast 
articial chromosome-1 （YAC-1） lymphoma cells were maintained in RPMI 1640 medium 
supplemented with 10％ heat-inactivated fetal calf serum, 2 mM L-glutamine, 100 IU /
mL penicillin, 100μg / mL streptomycin, 10 mM HEPES buffer, 1 mM minimum essential 
medium （MEM） sodium pyruvate, and 0.1 mM MEM non-essential amino acids （complete 
medium ; CM） in a humidied incubator with 5％ CO2 in air at 37℃.  All cell culture 
reagents were purchased from Life Technologies （Gaithersburg, MD, USA）.  The YAC-1 
cells were used as target cells to assess non-specic killing in cytolytic assays.
　The MC38 cell line was genetically modified to produce murine IL-4 （MC38-IL4）, as 
described previously 25）.  Expression of IL-4 was conrmed by ELISA using a commercially 
available kit （mouse IL-4 ELISA ; PBL Biomedical Laboratories, New Brunswick, NJ, USA） 
according to the manufacturer’s instructions.  MC38 cells expressing the neomycin-resistance 
gene following retroviral transduction with MFG-Neo （MC38-Neo） were used as control 
cells 26）.  γ-Irradiation （100 Gy for tumor cells） was performed using a Gammacell 3000 
Elan （Nordion International, Kanata, Canada）.  As reported previously, 1×105 MC38-IL4 
cells produce approximately 360±108 ng IL-4 / 48 h, whereas wild-type MC38 （MC38-WT） 
cells do not produce any IL-4 25）.  IL-4 gene transduction does not affect the growth of 
tumor cells in vitro or the survival of γ-irradiated tumor cells 25）.
Therapeutic models
　To evaluate the potential to treat established tumors, we measured the size of established 
wild-type （WT） tumors in mice treated with genetically modied MC38 cells and antibody, 
as described previously 26）.  Briefly, B6 mice were injected with 1×105 MC38-WT cells 
subcutaneously （s.c.） into the right ank.  Then, 7, 10 and 14 days after WT inoculation, 
mice were treated with an injection of 1×105 genetically modied MC38 or 200μg anti-
Risa OMORI, et al130
PD-1 antagonistic Ab （BioLegend, San Diego, CA, USA）, alone or in combination, into the 
contralateral （left） ank.  Each experiment involved six mice per group.  Tumor size was 
measured twice a week using vernier calipers.  Experiments with the therapeutic model were 
performed three times.
Immunohistologic analysis
　B6 mice were injected with 1×105 MC38-WT cells s.c. in the right ank.  On Days 7, 10, 
and 14, mice were injected with 1×105 MC38-IL-4 and / or 200μg anti-PD-1 antagonistic 
Ab into the contralateral （left） ank.  Tumor tissues were harvested 4 days after the last 
inoculation （18 days after WT inoculation）, and were immediately embedded in optimal 
clotting temperature （OCT） compound （Tissue Tek, Elkhart, IN, USA） and frozen.  Serial 
5-μm sections were exposed to anti-CD4 and anti-CD8a Abs （Nippon Becton Dickinson, 
Tokyo, Japan） and anti-PDL1 Ab （BioLegend）.  Rat IgG2a （Nippon Becton Dickinson） 
was used as a control Ab.  Immunostaining was completed using a Vectastain ABC kit 
（Vector, Burlingame, CA, USA）.  Immunoreactive cells were counted in 10 elds using light 
microscopy at ×400 magnification in a blinded manner.  Each experiment involved two 
mice per group.
Induction of tumor-specic cytotoxic T lymphocytes
　Mice initially were inoculated with 1×105 MC38-IL4 tumor cells and / or 200μg anti-PD-1 
Ab on Days 0, 7, and 14.  Subsequently, on Day 28, MC38-immune mice were challenged 
with 3×105 MC38-WT cells.  Splenocytes （3×106 cells / mL） were harvested from these 
mice on Day 42 and were then stimulated in vitro with irradiated （100 Gy） MC38-WT 
tumor cells （3×105 cells / mL）.  Seven days later, responder cells （1×106 cells / mL） were 
restimulated with irradiated MC38-WT tumor cells （100 Gy ; 1×105 cells / mL） and syngeneic 
DCs （2×105 cells / mL） in the presence of 50 IU / mL recombinant mouse IL-2 （R&D 
Systems, Minneapolis, MN, USA）.  DCs were generated from bone marrow cells of B6 mice 
using murine granulocyte–macrophage colony stimulating factor （GM-CSF ; 10 ng / mL） and 
IL-4 （10 ng / mL）, obtained from Pepro Tech EC （London, UK）, as reported previously 27）. 
Cytolytic assays were performed 7 days after the last stimulation using the responder cells 
as effector cells.
Cytolytic assays
　Tumor-stimulated effector cells were assessed for cytolytic activity against MC38-WT and 
YAC-1 cells in triplicate in a 4-h 51Cr-release assay.  Target cells （1×106 cells / mL） were 
labeled with 3.7 MBq Na2 51CrO4 （Amersham Pharmacia Biotech, Tokyo, Japan） for 1 h 
at 37℃.  Labeled cells were washed and resuspended in CM.  Target cells （5×103） and 
various numbers of effector cells at specic effector-to-target ratios （E:T） were plated in 
200μL CM in each well of 96-well round-bottomed plates.  51Cr release was measured after 
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4 h incubation at 37℃.  Percent lysis was determined using the formula （release in assay
-spontaneous release）/（maximum release-spontaneous release）×100.  Maximum release 
was determined by lysis of labeled target cells with 1％ Triton X-100.  Spontaneous release 
was measured by incubating target cells in the absence of effector cells and was ＜15％ of 
maximum release.
Statistical analyses
　The comparative growth of established tumors and T cell responses were assessed using 
Student’s t-tests for two samples with unequal variance.  Differences between groups were 
considered signicant when P＜0.05.
Results
Therapeutic inoculations with IL-4-transduced MC38 tumor cells in combination with anti-
PD-1 Ab suppress the in vivo growth of established MC38 tumors
　We examined the therapeutic effects of MC38-IL4 and anti-PD-1 Ab.  Mice bearing 
established WT MC38 tumors were treated with injections of MC38-IL4 and anti-PD-1 Ab, 
either alone or in combination.  Starting 7 days after inoculation of MC38-WT, mice were 
injected every 3 days with the IL-4 cells and / or the Ab in the opposite ank.  The mean 
area of established tumors in mice treated with MC38-IL4 and MC38-IL4 plus the anti-
PD-1 Ab was signicantly less than that of tumors in the control group （203.2±31.9, 177.8±
23.9 and 309.5±27.6 mm2, respectively, on Day 28 ; P＝0.041 and P＝0.008, respectively ; Fig. 
1）.  Although there was a tendency for combination therapy with MC38-IL4 plus anti-PD-1 
Ab to suppress the growth of established tumors somewhat more effectively than MC38-IL4 
therapy alone, the difference failed to reach statistical signicance （P＝0.289）.
Combined MC38-IL4 plus anti-PD-1 Ab treatment induces CD4＋ and CD8＋ cell inltration 
into established WT tumors
　To analyze the antitumor mechanisms induced by combined MC38-IL4 plus anti-PD-1 
Ab therapy, we performed immunohistochemical staining using WT tumor tissues of treated 
mice.  Marked inltration of both CD4＋ and CD8＋ cells was observed following the addi-
tion of anti-PD-1 Ab compared with the control group and the group treated with MC38-
IL4 alone （Table 1 ; Fig. 2）.  These results suggest that the antitumor effect of MC38-IL4 
plus anti-PD-1 Ab combination therapy is dependent on both CD4＋ and CD8＋ cells.
Marked tumor-specific cytolysis is detected when splenocytes from mice treated with both 
MC38-IL4 and anti-PD-1 Ab are used as effector cells
　Mice were initially inoculated with MC38-IL4 and / or anti-PD-1 Ab on Days 0, 7, and 14. 
Subsequently, these mice where challenged with MC38-WT cells on Day 28.  Splenocytes 
were harvested from the treated mice on Day 35 and were stimulated weekly twice in vitro 
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with MC38-IL4 cells.  Cytolytic assays against MC38 or YAC-1 cells, which are sensitive for 
NK cells, were performed 7 days after the second stimulation.  High specicity for MC38 
was observed when mice were treated with MC38-IL4 alone （17.9±3.5％ for MC38 vs 9.5
±2.9％ for YAC-1 ; E:T＝20, P＝0.032 ; Fig. 3） or in combination with anti-PD-1-Ab （27.4
±4.6％ for MC38 vs 16.9±3.9％ for YAC-1 ; E:T＝20 ; P＝0.039）.  When splenocytes from 
mice treated with the anti-PD-1 Ab alone were used as effector cells, comparable cytolysis 
was detected for both MC38 and YAC-1 cells as target cells （18.6±5.9％ for MC38 vs 18.2
±2.7％ for YAC-1 ; E:T＝20 ; P＝0.231）.  Significant cytotoxicity was observed against 
MC38 cells in the group treated with the combination of IL-4 plus anti-PD-1 Ab compared 
with IL-4 alone （P＝0.046）.  These data suggest that the anti-PD-1 Ab has minimal ability 
Fig. 1. Therapeutic inoculation of IL-4-transduced MC38 tumor cells in combination with anti-PD-1 Ab sup-
presses the in vivo growth of established MC38 tumors. Mice were inoculated with MC38-WT cells in 
the ank on Day 0. On Day 7, mice were treated three times with injections of MC38-IL4 and anti-
PD-1 Ab, alone or in combination, into the contralateral ank every 3rd day starting 14 days after 
wild-type tumor injection. Six mice were studied in each group. Results show mean±SEM tumor area 
（mm2）, with signicance at 95％ condence limits indicated. This experiment was performed twice with 
similar results.
Table 1. Immunohistologic analysis of CD4＋ and CD8＋ T 
cell inltration in the established wild-type tumors 
treated with MC38-IL and / or anti-PD1 antagonistic 
antibody.
Treatment
Number of positive cells





Immunoreactive cells were counted in 5 microscopic fields 
（×400） without-knowledge of the experimental group. 
Results are reported as mean number of positive cells±S.D.
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Fig. 2. There was marked infiltration of CD4＋ and CD8＋ cells into established wild-type tumors in mice 
inoculated with MC38-IL4 cells in combination with anti-PD-1 Ab. B6 mice were injected s.c. three 
times with MC38-IL4 cells and anti-PD-1 Ab, either alone or in combination, in the contralateral ank 
to that containing the established wild-type tumor. Tumor tissues were harvested 4 days after therapeu-
tic inoculation and were stained with anti-CD4 and anti-CD8 Abs. Immunoreactive cells were observed 
using light microscopy （×400）.
Fig. 3. Treatment with IL-4 in combination with anti-PD-1 Ab induced potent tumor-specic cytolysis. Mice 
were initially inoculated with MC38-IL4  cells and / or anti-PD-1 Ab on Days 0, 7 and 14. Subsequent-
ly, MC38-immune mice were challenged with MC38-WT cells on Day 28. Splenocytes were harvested 
from these mice on Day 42 and then stimulated in vitro with MC38-IL4 cells and syngeneic DCs twice 
weekly. A cytolytic assay against MC38, MCA205, or YAC-1 cells was performed 7 days after the last 
stimulation. Results show mean±SD percentage cytotoxicity. This experiment was performed twice with 
similar results. The cytolytic assay against MC38 was performed using an effector-to-target （E:T） ratio 
of 20.
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to induce tumor-specic cytotoxicity, but does enhance the strong specic response induced 
by IL-4.
Discussion
　IL-4, a representative Th2-type cytokine, is produced by Th2-type cells.  The Th2-type 
response is thought to suppress the generation of Th1 cells 28）, which are usually involved 
in antitumor immunity.  Although IL-4 is generally regarded as an inducer of Th2-type 
responses, recent studies clearly demonstrate that IL-4 has pleiotropic effects on immune 
cells of multiple lineages29） and that it plays an important role as an inducer of Th1-type 
immunity30）.  In particular, IL-4 supports DC maturation and promotes enhanced IL-12p70 
secretion from DCs4）.  IL-4 gene therapy for cancer using genetically engineered tumor cells 
has been shown to induce potent protective and therapeutic antitumor immunity in animal 
models29）.  IL-4 induces tumor-specic cellular immune responses that contribute to long-
lasting immunity against parental tumors, and we have previously reported that IL-4 appears 
to promote a Th1-type antitumor immune response that is enhanced in cooperation with 
interferon （IFN）-α25）.
　To further improve the antitumor effects of IL-4-based immune therapy, we focused on 
PD-1, which has been identied as a marker of exhausted T cells 15, 16）.  Because blockade 
of PD-1 signaling has been shown to improve clinical outcome and restore functional T cell 
responses in cancer23, 24）, we hypothesized that PD-1 blockade has the potential to enhance 
the Th1-type antitumor response elicited by IL-4 gene-transduced tumor-based vaccination 
therapy.  In the present study, we investigated the antitumor effects, as well as the underly-
ing mechanisms, of combined treatment with IL-4-transduced tumor cell vaccine therapy and 
PD-1 blockade.
　First we examined the therapeutic effect of IL-4-transduced tumor cells and the anti-
PD-1 Ab in an established tumor model.  Following treatment of tumor-bearing mice with 
MC38-IL4 and anti-PD-1 Ab, signicant suppression of the outgrowth of established tumors 
was observed in the combination treatment group.  Combination treatment with IL-4 plus 
anti-PD-1 Ab tended to suppress the growth of established tumors somewhat more effec-
tively than IL-4 alone, although the differences failed to reach statistical signicance.  We 
performed this experiment three times with similar results.  Thus, additive antitumor effects 
were observed using a combination of IL-4 plus anti-PD-1 Ab to treat established tumors.
　Immunohistologic analyses of established tumors in mice treated with anti-PD-1 Ab 
revealed marked inltration of both CD4＋ and CD8＋ cells compared with the control and 
MC38-IL4-treated groups.  These data are in accord with the results of a previous study 
that reported that blockade of PD-1 signaling pathways reversed T cell exhaustion and 
restored antitumor immunity24）.  Interestingly, in the present study the proliferation rate 
of splenocytes did not differ significantly between the control and anti-PD-1 Ab-treated 
groups in the setting of an in vitro culture （data not shown）.  It is likely that this apparent 
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discrepancy between in vitro and in vivo ndings is due to the condition and microenviron-
ment of the local tumor because it was conrmed by immunohistochemical staining that 
established MC38-WT tumors express abundant PD-L1 molecules （data not shown）.  These 
observations suggest that blockade of PD-1 will avoid lymphocyte apoptosis, and will main-
tain the survival and inltration of tumor-specic T cells in the local tumor environment, 
which contains abundant PD-L1 molecules.
　Although PD-1 blockade recruits lymphocytes to local tumor sites, the therapeutic effect 
of anti-PD-1 Ab treatment alone did not have marked effects.  To investigate this nding 
further, we tried to induce tumor-specic cytotoxic T lymphocytes （CTLs） from the spleno-
cytes of IL-4- or anti-PD-1-treated mice and performed cytolytic assays.  A high specicity 
for MC38 cells was observed following IL-4 treatment, whereas only non-specic cytolysis 
was detected following treatment with the anti-PD-1 Ab.  Furthermore, specific cytolysis 
against MC38 cells was more potent following combined IL-4 plus anti-PD-1 Ab treatment 
compared with IL-4 alone.  These observations suggest that IL-4 elicits tumor-specic CTLs, 
whereas blockade of PD-1 mainly maintains the specic response induced by IL-4.  This 
nding further supports the rationale behind the use of combination therapy because both 
IL-4 and blockade of PD-1 have antitumor effects, but these effects are mediated by differ-
ent mechanisms.
　Before tumor-based gene therapy can be performed, there are a number of issues that 
need to be considered, including dose determination, the site of therapeutic injection, and 
the therapeutic interval.  However, the most critical issue remains the establishment of cyto-
kine gene-transduced tumor cells for individual patients.  Thus, new techniques may need to 
be developed to allow the transduction of targeted genes to a patient’s cells.
　Overall, the findings of the present study suggest that combination therapy with IL-4 
and PD-1 blockade has potent antitumor effects on established tumors via the induction 
of potent Th1-type immune responses in the host.  This form of combination therapy may 
be a candidate for ultimate application in the clinical treatment of cancer, although further 
investigations are required before clinical trials can be started.
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